Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.
波士頓，2024年11月26日（環球新聞社）—Aura Biosciences，Inc.（納斯達克：AURA），一家臨床階段的生物技術公司，正在開發用於保留器官功能的固體腫瘤精準療法，今天宣佈Elisabet de los Pinos博士，首席執行官，將於2024年12月3日星期二下午2:35在第7屆Evercore ISI HealthCONx大會上參加爐邊談話。
The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at , where a replay of the webcast will be archived for 90 days following the presentation date.
爐邊談話的現場網絡直播將在公司網站的「投資者與媒體」頁面的「事件與演示文稿」部分上提供，網站上將存檔網絡直播的重播，持續90天直到演示日期結束。
About Aura Biosciences
關於Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Aura生物科學是一家臨床階段的生物技術公司，專注於開發用於保護器官功能的固體腫瘤精準療法。我們的首席候選藥物bel-sar（AU-011）目前在初級脈絡膜黑色素瘤的後期開發階段，並在其他眼科腫瘤適應症和膀胱癌的早期開發階段。Aura生物科學總部位於馬薩諸塞州波士頓。我們的使命是成長爲一家創新的全球腫瘤公司，積極改善患者的生活。
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
欲了解更多信息，請訪問aurabiosciences.com。您可以在X（以前叫做Twitter） @AuraBiosciences上關注我們，並在LinkedIn上訪問我們的主頁。
Investor Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
投資者聯繫人：
Alex Dasalla
投資者關係和企業溝通主管
IR@aurabiosciences.com
Media Contact:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
媒體聯繫：
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
譯文內容由第三人軟體翻譯。
